On Invalid Date, Actinium Pharmaceuticals (NYSEMKT: ATNM) reported Q4 2023 earnings per share (EPS) of -$0.33, up 23.26% year over year. Total Actinium Pharmaceuticals earnings for the quarter were -$9.32 million. In the same quarter last year, Actinium Pharmaceuticals's earnings per share (EPS) was -$0.43.
As of Q2 2024, Actinium Pharmaceuticals's earnings has grown year over year. Actinium Pharmaceuticals's earnings in the past year totalled -$48.82 million.
What is ATNM's earnings date?
Actinium Pharmaceuticals's earnings date is Invalid Date. Add ATNM to your watchlist to be reminded of ATNM's next earnings announcement.
What was ATNM's revenue last quarter?
On Invalid Date, Actinium Pharmaceuticals (NYSEMKT: ATNM) reported Q4 2023 revenue of $81.00 thousand up Infinity% year over year. In the same quarter last year, Actinium Pharmaceuticals's revenue was $0.00.
What was ATNM's revenue growth in the past year?
As of Q2 2024, Actinium Pharmaceuticals's revenue has grown -92.14% year over year. This is 245.99 percentage points lower than the US Biotechnology industry revenue growth rate of 153.85%. Actinium Pharmaceuticals's revenue in the past year totalled $81.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.